一種新技術叫做光學彌散成像和分光光度計，允許開展無創(chuàng)傷、直接、實時地測定局部氧飽和度，而且費用低廉。新型組織血氧測定儀整合了這項技術，已經(jīng)獲得了美國食品藥物管理局地許可。

新型血氧測定儀叫做ODISsey，是由ViOptix公司研制開發(fā)的，該公司是一家組織氧測定設備的開發(fā)商和制造商。新技術將做為診斷與監(jiān)測設備，臨床用途極為廣泛。

ViOptix公司總裁兼首席執(zhí)行官Mohamed Elmandjra指出：“對我們公司以及對無創(chuàng)性組織氧檢測而言，這是一項重要成就。我們致力于發(fā)展各種創(chuàng)新產(chǎn)品，對健康保健市場具有極高的臨床應用價值。食品藥品管理局的許可對我們達到該目標是一個重要的里程碑?！?/P>

Novel Tissue Oximeter Technology
 
New technology called optical diffusion imaging and spectroscopy (ODIS) enables noninvasive, direct, real-time estimation of local tissue oxygen saturation (StO2) on a very cost-effective basis. A new tissue oximeter incorporating the technology has been cleared by the U.S. Food and Drug Administration (FDA).

The new oximeter is called ODISsey and was developed by ViOptix (Fremont, CA, USA), a developer and manufacturer of tissue oxygen measuring devices. The new technology will be used in diagnostic and monitoring equipment for a wide variety of clinical applications.

“This is a key achievement for us and for noninvasive tissue oxygen assessment in general,” noted Mohamed Elmandjra, president and CEO of ViOptix. “We are committed to bringing innovative products with high clinical value to the healthcare market, and FDA clearance is definitely a major milestone toward that goal.”